These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 911610)

  • 41. Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration.
    Suri A; Grundy BL; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Jan; 35(1):1-8. PubMed ID: 9021434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Studies on the protection against misonidazole-induced toxicity by antiinflammatory agents.
    Millar BC; Chaplin DJ; Jinks S
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 12():303-8. PubMed ID: 6221607
    [No Abstract]   [Full Text] [Related]  

  • 43. Influence of a prostaglandin-inhibiting drug on muscle soreness after eccentric work.
    Kuipers H; Keizer HA; Verstappen FT; Costill DL
    Int J Sports Med; 1985 Dec; 6(6):336-9. PubMed ID: 4077362
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determination of flurbiprofen in human plasma using gas chromatography-mass spectrometry with selected ion monitoring.
    Kawahara K; Matsumura M; Kimura K
    J Chromatogr; 1981 Apr; 223(1):202-7. PubMed ID: 7251765
    [No Abstract]   [Full Text] [Related]  

  • 45. Flurbiprofen analysis in plasma and breast milk by high-performance liquid chromatography.
    Johnson VA; Wilson JT
    J Chromatogr; 1986 Oct; 382():367-71. PubMed ID: 3782406
    [No Abstract]   [Full Text] [Related]  

  • 46. Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration.
    Kai S; Kondo E; Kawaguchi Y; Kitamura N; Yasuda K
    Br J Clin Pharmacol; 2013 Mar; 75(3):799-804. PubMed ID: 22822928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Definition of nonresponse to analgesic treatment of arthritic pain: an analytical literature review of the smallest detectable difference, the minimal detectable change, and the minimal clinically important difference on the pain visual analog scale.
    Stauffer ME; Taylor SD; Watson DJ; Peloso PM; Morrison A
    Int J Inflam; 2011; 2011():231926. PubMed ID: 21755025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.
    Scott DL; Smolen JS; Kalden JR; van de Putte LB; Larsen A; Kvien TK; Schattenkirchner M; Nash P; Oed C; Loew-Friedrich I;
    Ann Rheum Dis; 2001 Oct; 60(10):913-23. PubMed ID: 11557646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.
    Davies NM; Skjodt NM
    Clin Pharmacokinet; 2000 May; 38(5):377-92. PubMed ID: 10843458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical response to non-steroidal anti-inflammatory drugs in urate-crystal induced inflammation: a simultaneous study of intersubject and intrasubject variability.
    Walker JS; Nguyen TV; Day RO
    Br J Clin Pharmacol; 1994 Oct; 38(4):341-7. PubMed ID: 7833224
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nonsteroidal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use.
    Cashman J; McAnulty G
    Drugs; 1995 Jan; 49(1):51-70. PubMed ID: 7705216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation plasma levels, NSAID and therapeutic response.
    Famaey JP
    Clin Rheumatol; 1985 Jun; 4(2):124-32. PubMed ID: 3891199
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitation of dose and concentration-effect relationships for fenclofenac in rheumatoid arthritis.
    Dunagan FM; McGill PE; Kelman AW; Whiting B
    Br J Clin Pharmacol; 1986 Apr; 21(4):409-16. PubMed ID: 3518772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs.
    Lin JH; Cocchetto DM; Duggan DE
    Clin Pharmacokinet; 1987 Jun; 12(6):402-32. PubMed ID: 3301150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variability in response to NSAIDs. Fact or fiction?
    Day RO; Graham GG; Williams KM; Brooks PM
    Drugs; 1988 Dec; 36(6):643-51. PubMed ID: 3065056
    [No Abstract]   [Full Text] [Related]  

  • 56. The problems and pitfalls of NSAID therapy in the elderly (Part II).
    Johnson AG; Day RO
    Drugs Aging; 1991 May; 1(3):212-27. PubMed ID: 1794015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-inflammatory analgesic drug responders and non-responders: a clinico-pharmacological study of flurbiprofen.
    Capell HA; Konetschnik B; Glass RC
    Br J Clin Pharmacol; 1977 Oct; 4(5):623-4. PubMed ID: 911610
    [No Abstract]   [Full Text] [Related]  

  • 58. Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases.
    Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1979 Dec; 18(6):417-38. PubMed ID: 391529
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential effects of flurbiprofen and aspirin on acetazolamide disposition in humans.
    Sweeney KR; Chapron DJ; Antal EJ; Kramer PA
    Br J Clin Pharmacol; 1989 Jun; 27(6):866-9. PubMed ID: 2757898
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.